...A. 2022 Accomplishments: Exits this year with positive commercial momentum, driven by strong volume-based growth, including incretin products, which have seen unprecedented demand. 1. Manufacturing team stepped up to challenge, producing Trulicity and Mounjaro at volumes ahead of Co.'s internal plan. a. b. In addition to this commercial momentum, made significant pipeline progress, highlighted by: i. Positive SURMOUNT-1 study for tirzepatide in patients with obesity. ii. Successful regulatory submissions for four other new potential medicines that could launch by 2023-end. 2. Looking forward to 2023 and years beyond, has confidence in existing commercial portfolio and four potential launches of pirtobrutinib, donanemab, mirikizumab and lebrikizumab, which could serve as catalysts for growth through balance of this decade. Plans to step up investment across manufacturing and commercial organizations to build additional capacity and support successful launches for long term. a. 3. While Co.'s...